## **CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

ELI LILLY AND COMPANY

Kkades

Date /2-23-97

PATENT APPLICATION

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

pplicants : Brader, et al.

Serial No. : 08/484,542

) Group Art Unit:

Filed : 7 June 1995 ) 1813

For : Stabilized Acylated Insulin

Formulations ) Examiner:

) Allen,

Docket No. : X-10097

## DECLARATION UNDER 37 C.F.R. §1.131

Assistant Commissioner for Patents Washington, D. C. 20231

BEST AVAILABLE COPY

Sir:

We, Mark L. Brader and Michael J. Beckage, declare that:

We are co-inventors and applicants in this application.

Attached exhibits 1, 2, and 3 are copies of pages from Michael J. Beckage's notebook in which he recorded the preparation of a formulation comprising an aqueous solution of a fatty acid-acylated insulin and approximately 0.35 mole of zinc per mole of said fatty acid-acylated insulin, and having a pH of approximately 7.5. The fatty-acid acylated insulin was N<sup>E</sup>-Lys<sup>B29</sup>-palmitoyl-human insulin, which is referred to as C16-insulin. The formulation also contained m-cresol, a phenolic compound, at a concentration of approximately 2.5 mg/mL. The dates have been redacted.

All the actions, events, and observations described in exhibits 1, 2, and 3 occurred in the United States, prior to 23 March 1995.

We further declare that all statements made herein of our own knowledge are true, that all statements made on information and belief are believed to be true, and that these

statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both (18 U.S.C. 1001), and may jeopardize the validity of the application or any patent issuing thereon.

Mark L. Brades

**BEST AVAILABLE COPY**